Marwan G. Fakih, MD

Articles

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

June 27th 2024

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Unmet Needs Surrounding mCRC Treatment

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Considerations for Platinum-based Therapy

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

Consideration for Fruquintinib Dosing and Titration

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

FRESCO-2 Study Highlights

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Fruquintinib MoA and Toxicity Profile Overview

February 29th 2024

Key safety considerations for the use of fruquintinib are explored.

Evaluating 3L Treatment Landscape Evolution

February 22nd 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Overview of Current mCRC Treatment Landscape

February 22nd 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.